| Title: |
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC |
| Authors: |
de Castro, G., Jr.; Rizvi, N.A.; Schmid, P.; Syrigos, K.; Martin, C.; Yamamoto, N.; Cheng, Y.; Moiseyenko, V.; Summers, Y.; Vynnychenko, I.; Lee, S.Y.; Bryl, M.; Zer, A.; Erman, M.; Timcheva, C.; Raja, R.; Naicker, K.; Scheuring, U.; Walker, J.; Mann, H.; Chand, V.; Mok, T.; NEPTUNE Investigators |
| Publisher Information: |
2023 |
| Document Type: |
Electronic Resource |
| Abstract: |
Introduction: NEPTUNE, a phase 3, open-label study, evaluated first-line durvalumab plus tremelimumab versus chemotherapy in metastatic NSCLC (mNSCLC). Methods: Eligible patients with EGFR and ALK wild-type mNSCLC were randomized (1:1) to first-line durvalumab (20 mg/kg every 4 weeks until progression) plus tremelimumab (1 mg/kg every 4 weeks for up to four doses) or standard chemotherapy. Randomization was stratified by tumor programmed death-ligand 1 expression (≥25% versus |
| Index Terms: |
scientific_publication_article; Scientific publication - Journal Article |
| URL: |
https://pergamos.lib.uoa.gr/uoa/dl/object/3343661; https://worldcat.org/search?q=on:GRNKU+https://pergamos.lib.uoa.gr/uoa/dl/frontend/oaipmh+scientific_publication_article+CNTCOLL |
| Availability: |
Open access content. Open access content; Creative Commons Attribution-NonCommercial 4.0 (CC-BY-NC) |
| Note: |
English |
| Other Numbers: |
GRNKU oai:lib.uoa.gr:uoadl:3343661; uoadl:3343661; 1478896331 |
| Contributing Source: |
NATIONAL & KAPODISTRIAN UNIV OF ATHENS; From OAIster®, provided by the OCLC Cooperative. |
| Accession Number: |
edsoai.on1478896331 |
| Database: |
OAIster |